Summary of vital signs data

Vital signs showed increases in temperature and some transient increases in blood pressure on dosing days were seen with no apparent trends.

Twenty four (39%) subjects had clinically significant raised temperatures reported during the study. No subjects had temperatures >40°C. There was no clear dose effect.

A total of 30 (49%) subjects had systolic and/or diastolic blood pressure recordings meeting Common Terminology Criteria for Adverse Events (CTCAE) grade 3 which was considered clinically significant in 13 subjects. It should be noted that the majority of these subjects had an ongoing medical history of hypertension. The raised blood pressure was usually transient. There were no recorded falls in systolic blood pressure to below 90 mmHg or diastolic blood pressure below 50 mmHg in either phase of the study.

Fluctuations in heart rate were observed. Four subjects had clinically significant tachycardia reported meeting CTCAE grade 1 criteria. In one of these subjects a heart rate of 152 beats per minute was recorded after dosing with 1×10^{13} viral particles of enadenotucirev. This subject had a dose limiting toxicity of acute lung injury after dosing. There were no recorded decreases in heart rate to below 50 bpm in either phase of the study.